http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 12 Mar 2026 09:55:50 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Options/Increasing+unusual+put+option+volume%3A++ALDX+DKS+BMBL+BBBY+LWLG+BURL+DHT+SCO+PATH/26150799.html <p>Increasing unusual put option volume: ALDX DKS BMBL BBBY LWLG BURL DHT SCO PATH</p> http://www.streetinsider.com/Options/Increasing+unusual+put+option+volume%3A++ALDX+DKS+BMBL+BBBY+LWLG+BURL+DHT+SCO+PATH/26150799.html Thu, 12 Mar 2026 09:55:50 -0400 ALDX http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Aldeyra+Therapeutics%2C++++++++++++++++/26083415.html si-local-file:///var/storage/secattach/20260227/26083415.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Aldeyra+Therapeutics%2C++++++++++++++++/26083415.html Fri, 27 Feb 2026 17:07:00 -0400 ALDX O.08519002 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Aldeyra+Therapeutics%2C++++++++++++++++/26083415.html si-local-file:///var/storage/secattach/20260227/26083415.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Aldeyra+Therapeutics%2C++++++++++++++++/26083415.html Fri, 27 Feb 2026 17:07:00 -0400 ALDX O.08519002 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Aldeyra+Therapeutics%2C+++++For%3A+Dec+31/26082986.html si-local-file:///var/storage/secattach/20260227/26082986.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Aldeyra+Therapeutics%2C+++++For%3A+Dec+31/26082986.html Fri, 27 Feb 2026 16:47:00 -0400 ALDX O.08519002 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Aldeyra+Therapeutics%2C+++++For%3A+Dec+31/26082986.html si-local-file:///var/storage/secattach/20260227/26082986.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Aldeyra+Therapeutics%2C+++++For%3A+Dec+31/26082986.html Fri, 27 Feb 2026 16:47:00 -0400 ALDX O.08519002 http://www.streetinsider.com/Press+Releases/Aldeyra+Therapeutics+to+Participate+in+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26017668.html <p> LEXINGTON, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aldeyra.com&amp;esheet=54426843&amp;newsitemid=20260218490480&amp;lan=en-US&amp;anchor=Aldeyra+Therapeutics%2C+Inc.&amp;index=1&amp;md5=07249fb8acb29788c6e2283ed024b786" shape="rect">Aldeyra Therapeutics, Inc.</a> (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate virtually in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. </p><p> Dr. Brady’s conversation with Andreas Argyrides, Managing Director, Senior Biotech Analyst at Oppenheimer &amp; Co. Inc., is scheduled to begin at 10:40 a.m. ET Wednesday, February 25, 2026. To view the live webcast, log in to the Investors &amp; Media section http://www.streetinsider.com/Press+Releases/Aldeyra+Therapeutics+to+Participate+in+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26017668.html Wed, 18 Feb 2026 07:01:00 -0400 A.50202486 ALDX O.00047285 O.08519002 http://www.streetinsider.com/Press+Releases/Aldeyra+Therapeutics+to+Participate+in+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26017668.html <p> LEXINGTON, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aldeyra.com&amp;esheet=54426843&amp;newsitemid=20260218490480&amp;lan=en-US&amp;anchor=Aldeyra+Therapeutics%2C+Inc.&amp;index=1&amp;md5=07249fb8acb29788c6e2283ed024b786" shape="rect">Aldeyra Therapeutics, Inc.</a> (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate virtually in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. </p><p> Dr. Brady’s conversation with Andreas Argyrides, Managing Director, Senior Biotech Analyst at Oppenheimer &amp; Co. Inc., is scheduled to begin at 10:40 a.m. ET Wednesday, February 25, 2026. To view the live webcast, log in to the Investors &amp; Media section http://www.streetinsider.com/Press+Releases/Aldeyra+Therapeutics+to+Participate+in+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26017668.html Wed, 18 Feb 2026 07:01:00 -0400 A.50202486 ALDX O.00047285 O.08519002 http://www.streetinsider.com/Press+Releases/Aldeyra+Therapeutics+to+Participate+in+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26017668.html <p> LEXINGTON, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aldeyra.com&amp;esheet=54426843&amp;newsitemid=20260218490480&amp;lan=en-US&amp;anchor=Aldeyra+Therapeutics%2C+Inc.&amp;index=1&amp;md5=07249fb8acb29788c6e2283ed024b786" shape="rect">Aldeyra Therapeutics, Inc.</a> (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate virtually in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. </p><p> Dr. Brady’s conversation with Andreas Argyrides, Managing Director, Senior Biotech Analyst at Oppenheimer &amp; Co. Inc., is scheduled to begin at 10:40 a.m. ET Wednesday, February 25, 2026. To view the live webcast, log in to the Investors &amp; Media section http://www.streetinsider.com/Press+Releases/Aldeyra+Therapeutics+to+Participate+in+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26017668.html Wed, 18 Feb 2026 07:01:00 -0400 A.50202486 ALDX O.00047285 O.08519002 http://www.streetinsider.com/Press+Releases/Aldeyra+Therapeutics+to+Participate+in+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26017668.html <p> LEXINGTON, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aldeyra.com&amp;esheet=54426843&amp;newsitemid=20260218490480&amp;lan=en-US&amp;anchor=Aldeyra+Therapeutics%2C+Inc.&amp;index=1&amp;md5=07249fb8acb29788c6e2283ed024b786" shape="rect">Aldeyra Therapeutics, Inc.</a> (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate virtually in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. </p><p> Dr. Brady’s conversation with Andreas Argyrides, Managing Director, Senior Biotech Analyst at Oppenheimer &amp; Co. Inc., is scheduled to begin at 10:40 a.m. ET Wednesday, February 25, 2026. To view the live webcast, log in to the Investors &amp; Media section http://www.streetinsider.com/Press+Releases/Aldeyra+Therapeutics+to+Participate+in+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26017668.html Wed, 18 Feb 2026 07:01:00 -0400 A.50202486 ALDX O.00047285 O.08519002 http://www.streetinsider.com/Business+Wire/Aldeyra+Therapeutics+to+Participate+in+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26017668.html <p> LEXINGTON, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aldeyra.com&amp;esheet=54426843&amp;newsitemid=20260218490480&amp;lan=en-US&amp;anchor=Aldeyra+Therapeutics%2C+Inc.&amp;index=1&amp;md5=07249fb8acb29788c6e2283ed024b786" shape="rect">Aldeyra Therapeutics, Inc.</a> (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate virtually in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. </p><p> Dr. Brady’s conversation with Andreas Argyrides, Managing Director, Senior Biotech Analyst at Oppenheimer &amp; Co. Inc., is scheduled to begin at 10:40 a.m. ET Wednesday, February 25, 2026. To view the live webcast, log in to the Investors &amp; Media section http://www.streetinsider.com/Business+Wire/Aldeyra+Therapeutics+to+Participate+in+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26017668.html Wed, 18 Feb 2026 07:01:00 -0400 A.50202486 ALDX O.00047285 O.08519002 http://www.streetinsider.com/Business+Wire/Aldeyra+Therapeutics+to+Participate+in+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26017668.html <p> LEXINGTON, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aldeyra.com&amp;esheet=54426843&amp;newsitemid=20260218490480&amp;lan=en-US&amp;anchor=Aldeyra+Therapeutics%2C+Inc.&amp;index=1&amp;md5=07249fb8acb29788c6e2283ed024b786" shape="rect">Aldeyra Therapeutics, Inc.</a> (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate virtually in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. </p><p> Dr. Brady’s conversation with Andreas Argyrides, Managing Director, Senior Biotech Analyst at Oppenheimer &amp; Co. Inc., is scheduled to begin at 10:40 a.m. ET Wednesday, February 25, 2026. To view the live webcast, log in to the Investors &amp; Media section http://www.streetinsider.com/Business+Wire/Aldeyra+Therapeutics+to+Participate+in+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26017668.html Wed, 18 Feb 2026 07:01:00 -0400 A.50202486 ALDX O.00047285 O.08519002 http://www.streetinsider.com/Business+Wire/Aldeyra+Therapeutics+to+Participate+in+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26017668.html <p> LEXINGTON, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aldeyra.com&amp;esheet=54426843&amp;newsitemid=20260218490480&amp;lan=en-US&amp;anchor=Aldeyra+Therapeutics%2C+Inc.&amp;index=1&amp;md5=07249fb8acb29788c6e2283ed024b786" shape="rect">Aldeyra Therapeutics, Inc.</a> (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate virtually in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. </p><p> Dr. Brady’s conversation with Andreas Argyrides, Managing Director, Senior Biotech Analyst at Oppenheimer &amp; Co. Inc., is scheduled to begin at 10:40 a.m. ET Wednesday, February 25, 2026. To view the live webcast, log in to the Investors &amp; Media section http://www.streetinsider.com/Business+Wire/Aldeyra+Therapeutics+to+Participate+in+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26017668.html Wed, 18 Feb 2026 07:01:00 -0400 A.50202486 ALDX O.00047285 O.08519002 http://www.streetinsider.com/Business+Wire/Aldeyra+Therapeutics+to+Participate+in+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26017668.html <p> LEXINGTON, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aldeyra.com&amp;esheet=54426843&amp;newsitemid=20260218490480&amp;lan=en-US&amp;anchor=Aldeyra+Therapeutics%2C+Inc.&amp;index=1&amp;md5=07249fb8acb29788c6e2283ed024b786" shape="rect">Aldeyra Therapeutics, Inc.</a> (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate virtually in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. </p><p> Dr. Brady’s conversation with Andreas Argyrides, Managing Director, Senior Biotech Analyst at Oppenheimer &amp; Co. Inc., is scheduled to begin at 10:40 a.m. ET Wednesday, February 25, 2026. To view the live webcast, log in to the Investors &amp; Media section http://www.streetinsider.com/Business+Wire/Aldeyra+Therapeutics+to+Participate+in+the+Oppenheimer+36th+Annual+Healthcare+Life+Sciences+Conference/26017668.html Wed, 18 Feb 2026 07:01:00 -0400 A.50202486 ALDX O.00047285 O.08519002 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Aldeyra+Therapeutics%2C++++++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26012005.html si-local-file:///var/storage/secattach/20260217/26012005.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Aldeyra+Therapeutics%2C++++++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26012005.html Tue, 17 Feb 2026 16:00:00 -0400 ALDX O.08519002 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Aldeyra+Therapeutics%2C++++++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26012005.html si-local-file:///var/storage/secattach/20260217/26012005.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Aldeyra+Therapeutics%2C++++++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26012005.html Tue, 17 Feb 2026 16:00:00 -0400 ALDX O.08519002 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aldeyra+Therapeutics%2C+++++For%3A+Dec+23/25794944.html si-local-file:///var/storage/secattach/20251231/25794944.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aldeyra+Therapeutics%2C+++++For%3A+Dec+23/25794944.html Wed, 31 Dec 2025 17:07:00 -0400 ALDX O.08519002 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aldeyra+Therapeutics%2C+++++For%3A+Dec+23/25794944.html si-local-file:///var/storage/secattach/20251231/25794944.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aldeyra+Therapeutics%2C+++++For%3A+Dec+23/25794944.html Wed, 31 Dec 2025 17:07:00 -0400 ALDX O.08519002 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aldeyra+Therapeutics%2C+++++For%3A+Dec+15/25743028.html si-local-file:///var/storage/secattach/20251216/25743028.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aldeyra+Therapeutics%2C+++++For%3A+Dec+15/25743028.html Tue, 16 Dec 2025 06:02:00 -0400 ALDX O.08519002 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aldeyra+Therapeutics%2C+++++For%3A+Dec+15/25743028.html si-local-file:///var/storage/secattach/20251216/25743028.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aldeyra+Therapeutics%2C+++++For%3A+Dec+15/25743028.html Tue, 16 Dec 2025 06:02:00 -0400 ALDX O.08519002 http://www.streetinsider.com/Corporate+News/Aldeyra+Therapeutics+receives+FDA+extension+for+dry+eye+drug+review/25742640.html <p>The U.S. Food and Drug Administration has extended the review period for Aldeyra Therapeutics Inc.'s (NASDAQ: ALDX) reproxalap drug application for dry eye disease treatment to March 16, 2026.</p><p>The FDA originally set a December 16, 2025 target action date under the Prescription Drug User Fee Act after accepting the New Drug Application for review on July 16, 2025. The application was submitted on June 16, 2025.</p><p>On December 12, 2025, the FDA requested that Aldeyra submit the Clinical Study Report for reproxalap's dry eye disease field trial to the drug application. The biotechnology company submitted the report the same day, which http://www.streetinsider.com/Corporate+News/Aldeyra+Therapeutics+receives+FDA+extension+for+dry+eye+drug+review/25742640.html Tue, 16 Dec 2025 03:57:40 -0400 ALDX http://www.streetinsider.com/FDA/Aldeyra+Therapeutics+receives+FDA+extension+for+dry+eye+drug+review/25742640.html <p>The U.S. Food and Drug Administration has extended the review period for Aldeyra Therapeutics Inc.'s (NASDAQ: ALDX) reproxalap drug application for dry eye disease treatment to March 16, 2026.</p><p>The FDA originally set a December 16, 2025 target action date under the Prescription Drug User Fee Act after accepting the New Drug Application for review on July 16, 2025. The application was submitted on June 16, 2025.</p><p>On December 12, 2025, the FDA requested that Aldeyra submit the Clinical Study Report for reproxalap's dry eye disease field trial to the drug application. The biotechnology company submitted the report the same day, which http://www.streetinsider.com/FDA/Aldeyra+Therapeutics+receives+FDA+extension+for+dry+eye+drug+review/25742640.html Tue, 16 Dec 2025 03:57:40 -0400 ALDX http://www.streetinsider.com/Press+Releases/Aldeyra+Therapeutics+Announces+PDUFA+Extension+of+the+New+Drug+Application+of+Reproxalap+for+the+Treatment+of+Dry+Eye+Disease/25742150.html <p> LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (NDA) for the treatment of dry eye disease. The extended PDUFA target action date is March 16, 2026. </p><p> Following submission on June 16, 2025, the NDA was accepted for review as a “complete class 2 response” by the FDA on July 16, 2025, with a target http://www.streetinsider.com/Press+Releases/Aldeyra+Therapeutics+Announces+PDUFA+Extension+of+the+New+Drug+Application+of+Reproxalap+for+the+Treatment+of+Dry+Eye+Disease/25742150.html Mon, 15 Dec 2025 19:30:00 -0400 A.06822034 ALDX O.08519002 O.20026344 http://www.streetinsider.com/Press+Releases/Aldeyra+Therapeutics+Announces+PDUFA+Extension+of+the+New+Drug+Application+of+Reproxalap+for+the+Treatment+of+Dry+Eye+Disease/25742150.html <p> LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (NDA) for the treatment of dry eye disease. The extended PDUFA target action date is March 16, 2026. </p><p> Following submission on June 16, 2025, the NDA was accepted for review as a “complete class 2 response” by the FDA on July 16, 2025, with a target http://www.streetinsider.com/Press+Releases/Aldeyra+Therapeutics+Announces+PDUFA+Extension+of+the+New+Drug+Application+of+Reproxalap+for+the+Treatment+of+Dry+Eye+Disease/25742150.html Mon, 15 Dec 2025 19:30:00 -0400 A.06822034 ALDX O.08519002 O.20026344 http://www.streetinsider.com/Press+Releases/Aldeyra+Therapeutics+Announces+PDUFA+Extension+of+the+New+Drug+Application+of+Reproxalap+for+the+Treatment+of+Dry+Eye+Disease/25742150.html <p> LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (NDA) for the treatment of dry eye disease. The extended PDUFA target action date is March 16, 2026. </p><p> Following submission on June 16, 2025, the NDA was accepted for review as a “complete class 2 response” by the FDA on July 16, 2025, with a target http://www.streetinsider.com/Press+Releases/Aldeyra+Therapeutics+Announces+PDUFA+Extension+of+the+New+Drug+Application+of+Reproxalap+for+the+Treatment+of+Dry+Eye+Disease/25742150.html Mon, 15 Dec 2025 19:30:00 -0400 A.06822034 ALDX O.08519002 O.20026344 http://www.streetinsider.com/Press+Releases/Aldeyra+Therapeutics+Announces+PDUFA+Extension+of+the+New+Drug+Application+of+Reproxalap+for+the+Treatment+of+Dry+Eye+Disease/25742150.html <p> LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (NDA) for the treatment of dry eye disease. The extended PDUFA target action date is March 16, 2026. </p><p> Following submission on June 16, 2025, the NDA was accepted for review as a “complete class 2 response” by the FDA on July 16, 2025, with a target http://www.streetinsider.com/Press+Releases/Aldeyra+Therapeutics+Announces+PDUFA+Extension+of+the+New+Drug+Application+of+Reproxalap+for+the+Treatment+of+Dry+Eye+Disease/25742150.html Mon, 15 Dec 2025 19:30:00 -0400 A.06822034 ALDX O.08519002 O.20026344